FDA approves Sanofi biosimilar product for treatment of diabetes
The U.S. Food and Drug Administration approved Merilog as biosimilar to Novolog for the improvement of glycemic control in adults and pediatric ...
Sanofi price target raised to EUR 110 from EUR 105 at JPMorgan
JPMorgan raised the firm’s price target on Sanofi (SNY) to EUR 110 from EUR 105 and keeps a Neutral rating on the shares.Maximize Your ...
Sanofi to take $250M charge on study failure for E. coli vaccine
The French drugmaker said the vaccine it agreed to develop with Johnson & Johnson a year ago was “not sufficiently effective.
J&J, Sanofi stop E.coli vaccine trial due to low effectiveness
Johnson & Johnson and partner Sanofi will stop a late-stage trial of an experimental vaccine to prevent infections caused by ...
J&J to discontinue E.coli vaccine candidate study
Johnson & Johnson said on Thursday it will discontinue a late-stage study of an experimental E.coli vaccine it was developing ...
Drugmaker Biogen Forecasts 2025 Profit Below Expectations
On an adjusted basis, Biogen expects 2025 profit between $15.25 and $16.25 per share. It earned $16.47 in 2024 and analysts ...
News Medical5d
BGStar Blood Glucose Monitor from Star Systems
Sanofi’s track record of creating effective solutions for people living with diabetes has lead to the development of the BGStarTM, a blood glucose monitoring device with the tools and a support ...
pharmaphorum1d
Teva, Sanofi score well with anti-TL1A drug in IBD test
Armed with positive data from a phase 2b trial, Teva and Sanofi have decided to push their anti-TL1A antibody duvakitug into a phase 3 programme in inflammatory bowel disease (IBD). The results of ...
pharmaphorum4d
Sanofi takes SK Bio-partnered pneumococcal shot into phase 3
Sanofi has moved ahead with plans to challenge Pfizer and MSD for a piece of the market for pneumococcal vaccines, taking a 21-valent shot licensed from SK Biosciences into phase 3 testing.